
|Articles|March 9, 2011
- December 2010
- Volume 4
- Issue 12
FDA Approves Zactima
Author(s)OBTN
An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease.
Advertisement
An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease. The panel expressed concerns about “substantial” drug-related toxicity associated with the 300-mg daily dose. Members said that patients taking Zactima appeared to be at greater risk for stroke and other cerebrovascular events and a prolonged QT interval.
Articles in this issue
almost 15 years ago
Medulloblastoma Subtypes Are Different Diseasesalmost 15 years ago
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myelomaalmost 15 years ago
FDA Requests Label Change for Generic DocetaxelAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































